Activation of the Hippo transducer TAZ is emerging as a novel oncogenic route in breast cancer and it has been associated with breast cancer stem cells. Additionally, TAZ expression has been linked with HER-2 positivity. We investigated the association between TAZ expression and pathological complete response in HER2-positive breast cancer patients treated with trastuzumab-based neoadjuvant therapy.TAZ was assessed in diagnostic core biopsies by immunohistochemistry. To categorize samples with low TAZ and samples with high TAZ we generated a score by combining staining intensity and cellular localization. The pathological complete response rate was 78.6% in patients with low TAZ tumors and 57.6% in patients with high TAZ tumors (p=0.082). In HER2-enriched tumors there was no signi cant association between TAZ and pathological complete response, whereas in the luminal B subtype the pathological complete response rate was 82.4% in tumors with low TAZ and 44.4% in tumors with high TAZ (p=0.035). This association remained statistically signi cant when restricting our analysis to triple-positive tumors with expression of both estrogen receptor and progesterone receptor ≥ 50% (p=0.035). Results from this exploratory study suggest that the TAZ score ef ciently predicts pathological complete response in Luminal B, HER2-positive breast cancer patients who received neoadjuvant chemotherapy and trastuzumab.

Vici, P., Mottolese, M., Pizzuti, L., Barba, M., Sperati, F., Terrenato, I., Di Benedetto, A., Natoli, C., Gamucci, T., Angelucci, D., Ramieri, M., Di Lauro, L., Sergi, D., Bartucci, M., Dattilo, R., Pagliuca, A., De Maria Marchiano, R., Maugeri-saccà, M., The Hippo transducer TAZ as a biomarker of pathological complete response in HER2-positive breast cancer patients treated with trastuzumab-based neoadjuvant therapy, <<ONCOTARGET>>, 2014; (5 (20)): 9619-9625. [doi:10.18632/oncotarget.2449] [http://hdl.handle.net/10807/111439]

The Hippo transducer TAZ as a biomarker of pathological complete response in HER2-positive breast cancer patients treated with trastuzumab-based neoadjuvant therapy

Gamucci, T;Sergi, D;De Maria Marchiano, R;
2014

Abstract

Activation of the Hippo transducer TAZ is emerging as a novel oncogenic route in breast cancer and it has been associated with breast cancer stem cells. Additionally, TAZ expression has been linked with HER-2 positivity. We investigated the association between TAZ expression and pathological complete response in HER2-positive breast cancer patients treated with trastuzumab-based neoadjuvant therapy.TAZ was assessed in diagnostic core biopsies by immunohistochemistry. To categorize samples with low TAZ and samples with high TAZ we generated a score by combining staining intensity and cellular localization. The pathological complete response rate was 78.6% in patients with low TAZ tumors and 57.6% in patients with high TAZ tumors (p=0.082). In HER2-enriched tumors there was no signi cant association between TAZ and pathological complete response, whereas in the luminal B subtype the pathological complete response rate was 82.4% in tumors with low TAZ and 44.4% in tumors with high TAZ (p=0.035). This association remained statistically signi cant when restricting our analysis to triple-positive tumors with expression of both estrogen receptor and progesterone receptor ≥ 50% (p=0.035). Results from this exploratory study suggest that the TAZ score ef ciently predicts pathological complete response in Luminal B, HER2-positive breast cancer patients who received neoadjuvant chemotherapy and trastuzumab.
Inglese
Vici, P., Mottolese, M., Pizzuti, L., Barba, M., Sperati, F., Terrenato, I., Di Benedetto, A., Natoli, C., Gamucci, T., Angelucci, D., Ramieri, M., Di Lauro, L., Sergi, D., Bartucci, M., Dattilo, R., Pagliuca, A., De Maria Marchiano, R., Maugeri-saccà, M., The Hippo transducer TAZ as a biomarker of pathological complete response in HER2-positive breast cancer patients treated with trastuzumab-based neoadjuvant therapy, <<ONCOTARGET>>, 2014; (5 (20)): 9619-9625. [doi:10.18632/oncotarget.2449] [http://hdl.handle.net/10807/111439]
File in questo prodotto:
File Dimensione Formato  
The Hippo transducer TAZ as a biomarker .pdf

accesso aperto

Tipologia file ?: Versione Editoriale (PDF)
Licenza: Creative commons
Dimensione 646.63 kB
Formato Adobe PDF
646.63 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/10807/111439
Citazioni
  • ???jsp.display-item.citation.pmc??? 21
  • Scopus 30
  • ???jsp.display-item.citation.isi??? 30
social impact